Study to determine if genotype determines response to AI's

[AlaskaAngel]

Aromatase Inhibitor for Treatment of Resected Grade I, II or III Breast Cancer

This study is currently recruiting patients.
Verified by Mayo Clinic August 2006

Sponsors and Collaborators:Mayo Clinic M.D. Anderson Cancer Center
Information provided by:Mayo ClinicClinicalTrials.gov Identifier:NCT00366054
Purpose

Study to determine if genotype determines response to Aromatase Inhibitors ie: Decrease in hormone and drug levels.
Condition Breast Cancer